Zevra Therapeutics Inc (ZVRA)

$13.98 +0.17 (1.23%)
Market Cap 826.43M
Revenue (ttm) 106.47M
Net Income (ttm) 83.23M
EPS (ttm) N/A
PE Ratio 10.87
Forward PE 24.66
Profit Margin 78.17%
Debt to Equity Ratio 0.00
Volume 1,422,300
Avg Vol 1,770,856
Day's Range N/A - N/A
Shares Out 59.12M
Stochastic %K 71%
Beta 0.85
Analysts Strong Sell
Price Target $28.25

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational p...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 958 1253
Address:
101 Federal Street, Suite 103, Boston, United States
Wahoos
Wahoos Jul. 4 at 4:48 PM
$ZVRA Let’s get on the July CHMP agenda for Approval!
0 · Reply
MandoTrades
MandoTrades Jul. 4 at 4:20 PM
$ZVRA
0 · Reply
suburbanfarmer
suburbanfarmer Jul. 4 at 12:34 PM
$ZVRA Happy 4th! 🇺🇸 🎇🎆
0 · Reply
MarketMaestro1
MarketMaestro1 Jul. 3 at 9:52 PM
In the past year: Biggest Gains: $ZVRA +80% $UNH +75% My biggest losers (unrealised)*: $NKE - 31% (under 1% of my portfolio) $ASPN -22% (0.5% of my portfolio) $GRAB -24% Looking to focus on the names setting up in good groups.. Next week’s portfolio and watchlist are live! Head back to my profile to get the latest trading strategies and market analysis.
0 · Reply
intowits
intowits Jul. 3 at 4:44 PM
$ZVRA This Monday we may see the July list of MMAs in process which will show the date Z responded to the 180 day LoQs: https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation
2 · Reply
intowits
intowits Jul. 3 at 4:39 PM
$ZVRA Just some friendly advice. If you drink a fifth on the Fourth, you may not go forth on the Fifth. Stay safe on our 250th Anniversary!
0 · Reply
DevAd
DevAd Jul. 3 at 4:30 PM
$ZVRA 2 months in Bali seeing this baby creeping to 20 and then 34. Less gooo!
0 · Reply
KemPharm_rocks
KemPharm_rocks Jul. 3 at 3:30 PM
$ZVRA I am guessing we have some international investors here, but for my American brothers and sisters 🇺🇸, sincere wishes for a great 250-year celebration of our great nation! 🎊 🎈 🎉
0 · Reply
steven1x
steven1x Jul. 3 at 3:14 PM
$ZVRA https://g.co/gemini/share/5c0c38d56700
0 · Reply
TheSandman89
TheSandman89 Jul. 3 at 1:28 PM
$ZVRA
2 · Reply
Latest News on ZVRA
Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports

2026-06-23T13:33:10.000Z - 11 days ago

Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports

Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

Jun 23, 2026, 7:30 AM EDT - 11 days ago

Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

Zevra Therapeutics chief medical officer to step down

2026-06-11T13:15:49.000Z - 23 days ago

Zevra Therapeutics chief medical officer to step down

Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

Jun 11, 2026, 8:30 AM EDT - 23 days ago

Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

Zevra Therapeutics price target raised to $35 from $25 at Maxim

2026-06-10T17:36:05.000Z - 24 days ago

Zevra Therapeutics price target raised to $35 from $25 at Maxim

Zevra Therapeutics price target raised to $29 from $25 at Guggenheim

2026-06-10T11:21:28.000Z - 24 days ago

Zevra Therapeutics price target raised to $29 from $25 at Guggenheim

Zevra Therapeutics price target raised to $27 from $23 at BTIG

2026-06-09T17:02:03.000Z - 25 days ago

Zevra Therapeutics price target raised to $27 from $23 at BTIG

Zevra Therapeutics price target raised to $29 from $24 at Canaccord

2026-06-09T11:10:50.000Z - 25 days ago

Zevra Therapeutics price target raised to $29 from $24 at Canaccord

Zevra Therapeutics price target raised to $25 from $18 at Citizens

2026-06-09T09:05:39.000Z - 25 days ago

Zevra Therapeutics price target raised to $25 from $18 at Citizens

Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald

2026-06-08T14:10:40.000Z - 26 days ago

Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald

Zevra Therapeutics announces Orange Book listing of Miplyffa patent

2026-06-08T11:47:57.000Z - 26 days ago

Zevra Therapeutics announces Orange Book listing of Miplyffa patent

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

Jun 8, 2026, 7:30 AM EDT - 26 days ago

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

Zevra Therapeutics Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 4 weeks ago

Zevra Therapeutics Slides: Corporate presentation

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 29, 2026, 4:30 PM EDT - 5 weeks ago

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 9:00 AM EDT - 6 weeks ago

Zevra Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Zevra Therapeutics price target raised to $25 from $23 at Guggenheim

2026-05-08T13:28:23.000Z - 2 months ago

Zevra Therapeutics price target raised to $25 from $23 at Guggenheim

Zevra Therapeutics reports Q1 EPS 60c, consensus 8c

2026-05-07T00:44:27.000Z - 2 months ago

Zevra Therapeutics reports Q1 EPS 60c, consensus 8c

Zevra Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Zevra Therapeutics Earnings Call Transcript: Q1 2026

Zevra Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Zevra Therapeutics Earnings release: Q1 2026

Zevra Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Zevra Therapeutics Quarterly report: Q1 2026

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

May 6, 2026, 4:05 PM EDT - 2 months ago

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Zevra Therapeutics Proxy statement: Proxy filing

Zevra Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Zevra Therapeutics Proxy statement: Proxy filing

Zevra Therapeutics Slides: Corporate presentation

Apr 6, 2026, 7:00 AM EDT - 3 months ago

Zevra Therapeutics Slides: Corporate presentation

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Mar 20, 2026, 4:30 PM EDT - 3 months ago

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics sells SDX portfolio to Commave for $50M

2026-03-16T11:35:43.000Z - 3 months ago

Zevra Therapeutics sells SDX portfolio to Commave for $50M

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Mar 16, 2026, 7:30 AM EDT - 3 months ago

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics initiated with a Buy at BTIG

2026-03-16T10:41:37.000Z - 3 months ago

Zevra Therapeutics initiated with a Buy at BTIG

Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:00 AM EDT - 4 months ago

Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Zevra Therapeutics price target raised to $23 from $22 at Guggenheim

2026-03-10T10:56:08.000Z - 4 months ago

Zevra Therapeutics price target raised to $23 from $22 at Guggenheim

Zevra Therapeutics Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Zevra Therapeutics Earnings Call Transcript: Q4 2025

Zevra Therapeutics Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Zevra Therapeutics Annual report: Q4 2025

Zevra Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Zevra Therapeutics Earnings release: Q4 2025

Zevra Therapeutics reports Q4 EPS 20c, consensus 5c

2026-03-09T20:20:20.000Z - 4 months ago

Zevra Therapeutics reports Q4 EPS 20c, consensus 5c

Zevra Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Zevra Therapeutics Slides: Corporate presentation

Zevra Therapeutics appoints Renz as Chief Financial Officer

2026-03-05T13:09:46.000Z - 4 months ago

Zevra Therapeutics appoints Renz as Chief Financial Officer

ARDX

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Mar 2, 2026, 7:30 AM EST - 4 months ago

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Zevra Therapeutics to Present at the Citizens Life Sciences Conference

Feb 25, 2026, 7:30 AM EST - 4 months ago

Zevra Therapeutics to Present at the Citizens Life Sciences Conference

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

Feb 24, 2026, 3:42 PM EST - 4 months ago

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 10:38 AM EST - 4 months ago

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

Feb 4, 2026, 7:30 AM EST - 5 months ago

Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

Feb 2, 2026, 7:30 AM EST - 5 months ago

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

Jan 26, 2026, 7:30 AM EST - 5 months ago

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

Zevra Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:45 PM EST - 6 months ago

Zevra Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Zevra Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:45 PM EST - 6 months ago

Zevra Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Dec 2, 2025, 7:30 AM EST - 7 months ago

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Zevra Therapeutics, Inc. Announces CFO Transition

Nov 20, 2025, 4:05 PM EST - 8 months ago

Zevra Therapeutics, Inc. Announces CFO Transition

Zevra Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 11:30 AM EST - 8 months ago

Zevra Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Zevra Therapeutics Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Zevra Therapeutics Earnings Call Transcript: Q3 2025

Zevra Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Zevra Therapeutics Quarterly report: Q3 2025

Zevra Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

Zevra Therapeutics Earnings release: Q3 2025

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Nov 5, 2025, 4:05 PM EST - 8 months ago

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Zevra Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 8 months ago

Zevra Therapeutics Slides: Corporate Presentation

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Oct 29, 2025, 7:30 AM EDT - 8 months ago

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Oct 27, 2025, 7:30 AM EDT - 8 months ago

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Sep 18, 2025, 7:30 AM EDT - 10 months ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Sep 4, 2025, 7:30 AM EDT - 10 months ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 11:30 AM EDT - 10 months ago

Zevra Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 28, 2025, 7:30 AM EDT - 11 months ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Aug 26, 2025, 7:30 AM EDT - 11 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Zevra Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 13, 2025, 1:00 PM EDT - 11 months ago

Zevra Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Zevra Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Zevra Therapeutics Earnings Call Transcript: Q2 2025

Zevra Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Zevra Therapeutics Quarterly report: Q2 2025

Zevra Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Zevra Therapeutics Earnings release: Q2 2025

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 12, 2025, 4:05 PM EDT - 11 months ago

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Zevra Therapeutics Slides: Corporate Presentation

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Zevra Therapeutics Slides: Corporate Presentation

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Aug 4, 2025, 7:30 AM EDT - 11 months ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jul 28, 2025, 6:00 AM EDT - 1 year ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Jul 18, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

Jul 16, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

Zevra Therapeutics Slides: Corporate Presentation

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Zevra Therapeutics Slides: Corporate Presentation

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025, 4:35 PM EDT - 1 year ago

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

Zevra Therapeutics Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025, 7:30 AM EDT - 1 year ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

Zevra Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:30 PM EDT - 1 year ago

Zevra Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Zevra Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q1 2025

Zevra Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Quarterly report: Q1 2025

Zevra Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q1 2025

Zevra Therapeutics Proxy statement: Proxy Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 11:30 AM EDT - 1 year ago

Zevra Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 6, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 17, 2025, 7:30 AM EDT - 1 year ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 1 year ago

Zevra Therapeutics Files Preliminary Proxy

Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q4 2024

Zevra Therapeutics Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Annual report: Q4 2024

Zevra Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q4 2024

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Zevra Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 10:30 AM EST - 1 year ago

Zevra Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 28, 2025, 7:30 AM EST - 1 year ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 27, 2025, 7:30 AM EST - 1 year ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 26, 2025, 9:46 AM EST - 1 year ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 1 year ago

Zevra to Participate at Upcoming Investor Conferences

Zevra Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 3:20 PM EST - 1 year ago

Zevra Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Zevra Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 2:30 PM EST - 1 year ago

Zevra Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 30, 2025, 7:30 AM EST - 1 year ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 29, 2025, 4:05 PM EST - 1 year ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Jan 8, 2025, 11:13 AM EST - 1 year ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 17, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes

Zevra Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 10:30 AM EST - 1 year ago

Zevra Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 21, 2024, 4:51 PM EST - 1 year ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 4:00 PM EST - 1 year ago

Zevra Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Zevra Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q3 2024

Zevra Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Quarterly report: Q3 2024

Zevra Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Earnings release: Q3 2024

Zevra Therapeutics Slides: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Slides: Q3 2024

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 11, 2024, 4:36 PM EST - 1 year ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Nov 6, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Wahoos
Wahoos Jul. 4 at 4:48 PM
$ZVRA Let’s get on the July CHMP agenda for Approval!
0 · Reply
MandoTrades
MandoTrades Jul. 4 at 4:20 PM
$ZVRA
0 · Reply
suburbanfarmer
suburbanfarmer Jul. 4 at 12:34 PM
$ZVRA Happy 4th! 🇺🇸 🎇🎆
0 · Reply
MarketMaestro1
MarketMaestro1 Jul. 3 at 9:52 PM
In the past year: Biggest Gains: $ZVRA +80% $UNH +75% My biggest losers (unrealised)*: $NKE - 31% (under 1% of my portfolio) $ASPN -22% (0.5% of my portfolio) $GRAB -24% Looking to focus on the names setting up in good groups.. Next week’s portfolio and watchlist are live! Head back to my profile to get the latest trading strategies and market analysis.
0 · Reply
intowits
intowits Jul. 3 at 4:44 PM
$ZVRA This Monday we may see the July list of MMAs in process which will show the date Z responded to the 180 day LoQs: https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation
2 · Reply
intowits
intowits Jul. 3 at 4:39 PM
$ZVRA Just some friendly advice. If you drink a fifth on the Fourth, you may not go forth on the Fifth. Stay safe on our 250th Anniversary!
0 · Reply
DevAd
DevAd Jul. 3 at 4:30 PM
$ZVRA 2 months in Bali seeing this baby creeping to 20 and then 34. Less gooo!
0 · Reply
KemPharm_rocks
KemPharm_rocks Jul. 3 at 3:30 PM
$ZVRA I am guessing we have some international investors here, but for my American brothers and sisters 🇺🇸, sincere wishes for a great 250-year celebration of our great nation! 🎊 🎈 🎉
0 · Reply
steven1x
steven1x Jul. 3 at 3:14 PM
$ZVRA https://g.co/gemini/share/5c0c38d56700
0 · Reply
TheSandman89
TheSandman89 Jul. 3 at 1:28 PM
$ZVRA
2 · Reply
MandoTrades
MandoTrades Jul. 3 at 12:30 AM
$ZVRA
0 · Reply
OrganicBlueberries
OrganicBlueberries Jul. 2 at 8:45 PM
$ZVRA
0 · Reply
InvestorRelations_
InvestorRelations_ Jul. 2 at 8:29 PM
$ZVRA well that was nice
0 · Reply
Smedley1
Smedley1 Jul. 2 at 8:21 PM
$ZVRA ?? what happened at close ??? volume/price spike
2 · Reply
KemPharm_rocks
KemPharm_rocks Jul. 2 at 8:08 PM
$ZVRA Well that was some impressive fireworks on display 🎆, in honor of our nations 250th anniversary. At exactly 3:50 p.m., shorts’ panic mode kicked in or tutes’ FOMO mode kicked in. Either way, me likey 🤗. Everyone knows July 13th could see Zevra’s MMA appear on the EMA’s July 20-23 agenda. That could mean one heck of an incoming Ring-Around-The-Rosey short-squeeze 😉.
1 · Reply
RoosterBoyLV
RoosterBoyLV Jul. 2 at 8:02 PM
$ZVRA nice strong finish today
0 · Reply
pavel3
pavel3 Jul. 2 at 7:29 PM
$ZVRA have a buy order @13.1
1 · Reply
pavel3
pavel3 Jul. 2 at 7:28 PM
$ZVRA at this point its very predictable, sell at high, buy at low....keep core to passive growth.
1 · Reply
111ggg
111ggg Jul. 2 at 2:32 PM
$ZVRA nice consolidation. Should see 12 next week.
1 · Reply
XL10
XL10 Jul. 2 at 2:23 PM
$ZVRA The stock sellers are doing a great job
0 · Reply
Biotechnicity
Biotechnicity Jul. 2 at 1:58 PM
$AMRN $CYTH $ZVRA I’m extremely close to closing my position here in $RFL Once the idiot longs return with their parked I.D.’s we know the hedge funds are locked and loaded to go short behind them because that’s where the money is — going short. P-3 data here is likely NOT STAT-SIG. However, as I’ve repeatedly suggested it DOESN’T HAVE TO BE. It’s not even the primary catalyst that has moved this share price sky high over the past month. I can support every facet of the above statement with TANGIBLE FACTS. Can you support the argument against that with something other than the “Beautiful Molecule” theory or the “they waited at 48-Weeks because the data was so good” nonsense/some sense theory? Please stop! Go back to sleep Cythians before the color we see today becomes the color we see everyday. I’m seeing red just responding to your passive rage.
0 · Reply
blotter
blotter Jul. 2 at 1:32 PM
$ZVRA I know it's an aggregator/a.i. poster below, but .96 EPS in Q4 2026 and .95 EPS in 2027 makes no sense Guessing it's pulling numbers from different analysts?
2 · Reply